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One-sentence summary: TKI-induced CD70 expression mediates drug resistance in LSCs. 
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Abstract 
 
In chronic myelogenous leukemia (CML), oncogenic BCR-ABL1 activates the Wnt pathway, which is 
fundamental for leukemia stem cell (LSC) maintenance. Tyrosine kinase inhibitor (TKI) treatment 
reduces Wnt-signaling in LSCs and often leads to molecular remission of CML; however, LSCs 
persist long-term despite BCR-ABL1 inhibition, ultimately leading to disease relapse. Here, we 
demonstrate that TKIs induce the expression of the tumor necrosis factor (TNF) family ligand CD70 
in LSCs by down-regulating microRNA-29, resulting in reduced CD70 promoter DNA methylation 
and up-regulation of the transcription factor specificity protein 1. CD70 triggered CD27-signaling and 
compensatory Wnt pathway activation. Consequently, combining TKIs with CD70 blockade 
effectively eliminated human CD34
+
 CML stem/progenitor cells in xenografts and LSCs in a murine 
CML model. Therefore, TKI-induced expression of CD70 and compensatory Wnt-signaling via the 
CD70/CD27-interaction is a promising targetable resistance mechanism of CML LSCs.  
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Introduction 
 
Chronic myelogenous leukemia (CML) originates from leukemia stem cells (LSCs) harboring the 
constitutively active BCR-ABL1 tyrosine kinase (1). Imatinib, a tyrosine kinase inhibitor (TKI) 
targeting BCR-ABL1, revolutionized CML therapy (2). TKI treatment can lead to long-term remission 
in CML patients; however, disease-initiating LSCs are resistant to TKIs despite BCR-ABL1 inhibition 
(3, 4). Therefore, definite cure of most patients is still not achievable and CML will ultimately relapse 
upon drug discontinuation (5). In addition, there is a substantial risk of TKI resistance due to 
mutations in BCR-ABL1 (5) and disease progression to blast phase (6). Consequently, future therapies 
must aim at eliminating LSCs by selectively targeting pathways that are crucial for LSC homeostasis. 
In CML, -catenin, a central component of the canonical Wnt pathway, is stabilized by BCR-ABL1 
(7) and is essential for LSC self-renewal (8). Therefore, -catenin deletion or its pharmacological 
inhibition eradicates TKI-resistant LSCs (9).  
CD27, a costimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily, is 
constitutively expressed on different immune cells and on hematopoietic and CML stem cells (10-12). 
We recently reported in a murine model that CD27-signaling in LSCs leads to CML progression (12). 
CD27-signaling is regulated by the expression of its only ligand CD70 (10). CD70 is not detectable in 
healthy individuals but is expressed on lymphocytes and subsets of dendritic cells upon immune 
activation. Therefore, activated CD70 expressing immune cells may contribute to CML progression 
(13). In addition, several solid tumors and lymphomas have been shown to express CD70, but the 
relevance and the physiological consequences of CD70 expression on cancer cells are controversial 
(10, 14). 
Here, we demonstrate that TKI-mediated BCR-ABL1 inhibition in leukemia cell lines and CD34
+
 
stem/progenitor cells from newly diagnosed CML patients induces expression of CD70 by down-
regulating microRNA (miR)-29 levels, resulting in reduced CD70 promoter DNA methylation and up-
regulation of the transcription factor specificity protein 1 (SP1). CD70 expression induced CD27-
signaling, compensatory Wnt pathway activation and TKI resistance. Co-treatment using TKIs and 
monoclonal antibodies blocking the CD70/CD27-interaction synergistically reduced leukemia cell 
proliferation and colony formation in vitro and effectively eradicated human CD34
+
 CML 
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stem/progenitor cells in murine xenografts in vivo. Similarly, in a murine CML model, combination 
therapy eradicated LSCs in a majority of treated animals. Our data reveal a therapeutically targetable 
mechanism of TKI resistance in CML LSCs. 
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Results 
TKI treatment induces CD70 expression in human leukemia cells. 
To analyze the impact of TKI treatment on CD70 expression, we cultured the BCR-ABL1
+
 CML cell 
line KBM5 in the presence of imatinib. Interestingly, imatinib induced CD70 mRNA and protein 
expression in a dose-dependent manner (Fig. 1A-C). The CD70 promoter contains binding sites for 
several transcription factors including SP1 and is methylation sensitive (15). Imatinib treatment 
resulted in up-regulation of SP1 and down-regulation of DNA methyltransferase 1 (DNMT1) mRNA 
expression (Fig. 1D-E). Similar results were obtained with the second-generation TKI nilotinib and in 
different BCR-ABL1
+
 leukemia cell lines such as K562 and SD-1 (fig. S1A-O). 
More importantly and in line with these findings, FACS-sorted CD34
+
 stem/progenitor cells from 
newly diagnosed CML patients (see table S1 for clinical characteristics of the included patients) 
cultured ex vivo in the presence of imatinib exhibited increased CD70 and SP1 mRNA expression, 
whereas DNMT1 was down-regulated (Fig. 1F-H). 
To elaborate whether the mechanism of TKI-mediated CD70 induction is dependent on BCR-ABL1 
inhibition or an off-target effect, we made use of the imatinib-resistant KBM5 cell line harboring the 
BCR-ABL1
T315I
 mutation (referred to as KBM5r). BCR-ABL1
T315I
 represents ~20% of all clinically 
observed BCR-ABL1 mutations and confers resistance to three TKIs currently used in clinics 
(imatinib, nilotinib and dasatinib) (16). At the therapeutic concentration of 1M, which is associated 
with an optimal response in CML patients (17), imatinib treatment did not increase the expression of 
CD70 protein and CD70 or SP1 mRNAs nor decrease the expression of DNMT1 mRNA in KBM5r 
cells (fig. S2A-E). Therefore, we cultured KBM5r cells in the presence of the pan-BCR-ABL1 
inhibitor ponatinib, which was developed to overcome BCR-ABL1
T315I
 mutation-mediated resistance 
(18) and has proven effective in clinical trials (19). Ponatinib treatment at the therapeutic 
concentration of 0.1M (19) induced CD70 protein and mRNA expression, up-regulated SP1 and 
down-regulated DNMT1 mRNA in KBM5r cells (Fig. 1I-M). CD70 protein expression was already 
up-regulated after 16 hours of treatment (fig. S3A), at a time point where ponatinib did not induce 
substantial cell death (fig. S3B). This indicates that the observed increase in CD70 expression after 
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TKI treatment is due to an up-regulation of the protein rather than a selection of CD70-expressing 
cells. 
To functionally prove that the expression of CD70 after TKI treatment is mediated by SP1, we stably 
knocked down SP1 in KBM5r cells using short hairpin (sh)SP1 lentiviral particles. SP1 knockdown 
KBM5r cells did not up-regulate CD70 in the presence of ponatinib compared to scrambled control 
RNA-transfected cells (Fig. 1N-P).  
To elaborate whether the Wnt pathway represents a link between TKI-mediated BCR-ABL1 inhibition 
and the regulation of CD70, SP1 and DNMT1, we cultured TKI-treated KBM5r cells in the presence of 
lithium chloride (20) or the specific Wnt activator R-Spondin 1 (21). Re-activation of Wnt-signaling 
by lithium or R-Spondin 1 blocked the changes observed after TKI treatment (fig. S4A-F).  
SP1 and DNMTs are regulated by miR-29 (22, 23). In addition, miR-29 has been shown to modulate 
Wnt-signaling in a positive feedback loop (23, 24). Therefore, we analyzed miR-29 levels in KBM5r 
cells treated with imatinib, nilotinib and ponatinib. Inhibition of BCR-ABL1
T315I
 by ponatinib resulted 
in down-regulation of all three miR-29s, whereas imatinib and nilotinib did not affect miR-29s (Fig. 
2A-C). Individual silencing of the three miR-29s using anti-miRs revealed that SP1 expression was 
increased after miR-29c silencing, whereas DNMT1 expression was suppressed after silencing of miR-
29a and miR-29b (Fig. 2D-E). 
The down-regulation of DNMT1 by TKI treatment prompted us to investigate the DNA methylation 
status of the CD70 promoter. Bisulfite sequencing revealed a strongly methylated CD70 promoter in 
vehicle-treated KBM5r cells that hardly expressed any detectable CD70 protein or mRNA (Fig. 1I-K, 
2F). Consistent with the up-regulation of CD70 mRNA and protein expression, ponatinib treatment 
significantly reduced CD70 promoter DNA methylation in KBM5r cells, particularly at the SP1 
binding site (Fig. 2F-H). Control KBM5r cells cultured in the presence of the DNMT inhibitor 
azacytidine, a de-methylating agent (25), showed similar reductions in CD70 promoter methylation 
(Fig. 2F-H). 
In summary, these data indicate that TKI-mediated blocking of BCR-ABL1, subsequent Wnt pathway 
inhibition and suppression of miR-29 induces CD70 expression by reducing its promoter methylation 
and up-regulating SP1. 
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Combined CD70/CD27 and BCR-ABL1 inhibition synergistically reduces Wnt-signaling and 
eradicates leukemia cells in vitro. 
SD-1 cells were cultured in the presence of either a blocking CD27 monoclonal antibody (mAb) or 
imatinib alone or both in combination. As previously reported (12), blocking the CD70/CD27-
interaction reduced SD-1 cell growth by inhibiting cell proliferation (Fig. 3A-B). In contrast, blocking 
CD27 signaling alone did not affect cell viability (Fig. 3C). In line with its documented ability to 
induce apoptosis of BCR-ABL1
+
 cells (26), imatinib treatment resulted in SD-1 cell death as analyzed 
by FACS (Fig. 3C). Imatinib reduced SD-1 cell growth and proliferation to a similar extent as CD27 
treatment (Fig. 3A-B). Interestingly, compared to single treatments, CD27/imatinib co-treatment 
significantly reduced cell growth by inhibiting cell proliferation and enhancing cell death (Fig. 3A-C). 
Similar results were obtained by treating SD-1 cells with CD27 mAb and nilotinib (Fig. 3D-F) and 
by treating KBM5 and KBM5r cells with CD27 mAb and imatinib or ponatinib, respectively (fig. 
S5). 
To investigate whether the treatment combination with CD27 mAb and imatinib resulted in 
synergistic activity, we performed a drug combination study according to the Chou-Talalay method 
(27). Co-treatment showed synergistic growth inhibition at all concentrations tested (Fig. 3G, fig. 
S6A-B and table S2).  
We could previously demonstrate that the CD70/CD27-interaction on murine CML LSCs activates the 
Wnt-signaling pathway (12). TKIs such as imatinib reduce aberrant BCR-ABL1-induced Wnt-
signaling in CML cells (7). To analyze if the synergistic effect on SD-1 cell viability and proliferation 
of CD27/imatinib co-treatment was mediated via Wnt pathway inhibition, we performed a lentiviral 
Wnt-signaling reporter assay and analyzed the expression of selected Wnt target genes. CD27 and 
imatinib single treatments similarly reduced Wnt-signaling and Wnt target gene transcription. 
Importantly, CD27/imatinib co-treatment inhibited Wnt pathway activation significantly stronger 
than each of the single compounds alone (Fig. 3H-I). In contrast, Notch, Hedgehog and MAP kinase 
pathways were not or only minimally affected by the CD27/imatinib co-treatment (fig. S6C). 
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CD70/CD27 and BCR-ABL1 co-inhibition promotes cell death of human CML stem/progenitor 
cells. 
Next, we investigated the functional role of increased CD27-signaling in response to imatinib-induced 
CD70 up-regulation in MACS-purified human CD34
+
 CML stem/progenitor cells. CD27 and CD70 
expression were determined by FACS (Figs. 4A-D). To analyze the level of the CD70/CD27-
interaction (CD27-signaling) in the different patient samples, we measured soluble CD27 (sCD27) in 
the cell supernatants. Ligation of CD27 by CD70 results in shedding of CD27 from the cellular 
membrane and release of sCD27 (10). Treatment of CD34
+
 CML stem/progenitor cells with a blocking 
human CD70 mAb (clone 41D12-D) resulted in up-regulation of membrane-bound CD27 (Figs. 
4A,C) and lower levels of sCD27 (Fig. 4E). The expression of CD70 was not altered after CD70 
mAb treatment (Fig. 4B,D). sCD27 levels were very comparable in all supernatants of untreated 
patient samples and were similarly reduced after CD70 treatment. This indicates that the level of 
CD27 ligation was quite similar between patient samples.  
Single treatments with either CD70 mAb or imatinib inhibited growth and proliferation of FACS-
sorted CD34
+
 CML stem/progenitor cells (Fig. 4F-G). The human CD70 mAb (clone 41D12-D) was 
specifically designed to block the CD70/CD27-interaction without inducing effector functions such as 
antibody-dependent cell-mediated or complement-mediated cytotoxicity and antibody-dependent cell-
mediated phagocytosis (28). In line with our results using the blocking CD27 mAb and SD-1 cells 
(Fig. 3A-F), single CD70 treatment inhibited cell proliferation without affecting cell viability, 
whereas single imatinib treatment reduced cell proliferation and induced cell death (Fig. 4G-I). 
Importantly, CD70/imatinib co-treatment potently reduced CD34+ CML stem/progenitor cells in 
liquid cultures by inhibiting cell proliferation and increasing cell death (Fig. 4G-I). In addition, colony 
formation in semi-solid cultures was significantly impaired by co-treatment compared to single 
treatments (Fig. 4J). Control CD34
+
 hematopoietic stem/progenitor cells from patients who underwent 
BM aspirate for other reasons than leukemia («healthy donors») were only marginally affected by 
CD70 or imatinib treatment in vitro (fig. S7A-E).  
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CD70/imatinib co-treatment eradicates human CD34+ CML stem/progenitor cells in murine 
xenografts. 
To validate our findings in vivo, we employed a previously described murine CML xenograft model 
(29, 30) using NOD/LtSz-scid IL2Rnull (NSG) mice (31). 2x106 MACS-sorted CD34+ CML 
stem/progenitor cells from the blood of patients 3, 4 and 5 carrying different BCR-ABL1 
translocations (table S1) were injected intravenously into sublethally irradiated (2.75 Gy) NSG mice. 
After seven days of engraftment, NSG mice were randomized to receive vehicle, imatinib or CD70 
treatment alone or CD70/imatinib co-treatment. Imatinib plasma levels in xenografted NSG mice 
were in the published therapeutic range of 1M (fig. S8) (17). After two weeks of treatment, animals 
were sacrificed and the BM was analyzed for human CD45
+
CD33
+
 CML myeloid cells and 
CD45
+
CD34
+
 CML stem/progenitor cells (Fig. 5A-E). At that time point, vehicle-treated NSG mice 
had a frequency of 11.8±1.1% of human CD45
+
CD33
+ 
CML myeloid cells in the BM (Fig. 5B). Single 
CD70 or imatinib treatment significantly reduced cell frequencies and absolute numbers of 
CD45
+
CD33
+
 leukemia cells and leukemia-initiating CD34
+
 CML stem/progenitor cells (Fig. 5C-E). 
CD70/imatinib co-treatment further reduced CD45+CD33+ CML myeloid cells (Fig. 5C-D) and, 
importantly, eradicated the leukemia-initiating CD34
+
 CML stem/progenitor cells in the BM of 9 out 
of 12 NSG mice (Fig. 5E).  
CD34
+
 CML stem/progenitor cells isolated ex vivo from xenografted vehicle-treated NSG mice 
expressed CD70 (Fig. 5F and fig. S9A) but only low levels of CD27 (fig. S9B-C). CD70 and CD27 
were not expressed on more differentiated CD34
-
 CML cells (Fig. 5F and fig. S9C). Imatinib treatment 
of xenografted NSG mice specifically increased CD70 expression on CD34
+
 CML stem/progenitor 
cells but not on CD34
-
 CML cells (Fig. 5F,G). In contrast, the expression of CD27 remained 
unchanged after TKI treatment (fig. S9C). In addition, imatinib treatment induced an up-regulation of 
SP1 and decreased the expression of DNMT1 and miR-29a, b and c in CD34
+
 CML stem/progenitor 
cells in vivo (Fig. 5H-L).  
To analyze if CD70 expression correlates with Wnt pathway activation in CML patients harboring the 
b3a2 or the b2a2 BCR-ABL1 translocation, we made use of expression data derived from a public 
repository for microarray data (accession number E-MEXP-480; http://www.ebi.ac.uk/arrayexpress). 
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Independent of the BCR-ABL1 translocation, CD70 expression positively correlated with the 
expression of Wnt target genes (Fig. 5M-N). 
 
 
TKI treatment induces CD70 expression in murine CML LSCs. 
Since human CD34
+
 CML stem/progenitor cells do not engraft long-term in NSG mice (29), we also 
tested our co-treatment strategy in a well-established syngeneic CML model (12). BM from donor 
BL/6 mice was transduced with BCR-ABL1-GFP and injected into sublethally irradiated (4.5 Gy) 
recipients. First, we intended to study the effects of imatinib single treatment on the expression of 
CD70 protein and Cd70, Sp1 and Dnmt1 mRNA in murine LSCs in vivo. In analogy to murine 
hematopoietic stem cells (HSCs) (32), murine LSCs reside in a BM cell population characterized by 
the lack of lineage markers and by the expression of stem cell antigen-1 (Sca-1) and c-kit (lin
-
Sca-1
+
c-
kit
hi
 cells, LSKs, fig. S10) (33). CML-bearing mice were either treated with vehicle or imatinib and 
CD70 expression in BCR-ABL1-GFP
+
 LSKs was analyzed. Consistent with our data obtained for 
KBM5 cells and human CD34
+
 CML stem/progenitor cells in vitro, BCR-ABL1-GFP
+
 LSKs from 
imatinib-treated CML mice expressed significantly higher levels of CD70 protein and mRNA as 
compared to BCR-ABL1-GFP
+
 LSKs from vehicle-treated mice (Fig. 6A-C and fig. S10). Moreover, 
imatinib treatment increased Sp1 and decreased Dnmt1 mRNA in BCR-ABL1-GFP
+
 LSKs (Fig. 6D-
E). Importantly, CD70 up-regulation upon imatinib treatment was specific for BCR-ABL1-GFP
+
 
LSKs, as imatinib did not alter CD70 expression on BCR-ABL1-GFP
+
c-kit
hi
Sca-1
-
 leukemia 
progenitors (fig. S10 and fig. S11A). Furthermore, CD70, Sp1 and Dnmt1 expression did not change in 
endogenous non-malignant GFP
-
 LSKs upon imatinib treatment (Fig. 6A and fig. S11B-E).  
As previously demonstrated, the CD70/CD27-interaction on murine CML LSCs activates the Wnt-
signaling pathway via TNF receptor associated factor 2 (TRAF2) and the TRAF2- and NCK-
interacting protein kinase (TNIK) (12). Even though imatinib treatment did not affect CD27 
expression on BCR-ABL1-GFP
+
 LSKs, Traf2 and Tnik were up-regulated on mRNA level while Wnt 
target genes such as Runx1 and Myc were down-regulated (fig. S11F-J). These results are in line with 
and further support the hypothesis that TKIs specifically alter the expression of CD70, SP1 and 
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DNMT1 via BCR-ABL1 inhibition and increase the expression of CD27 downstream signaling 
molecules such as TRAF2 and TNIK. 
 
 
CD70/imatinib combination therapy eliminates murine CML LSCs in vivo. 
In a second step, we intended to analyze the effect of combining TKI treatment with CD70/CD27 
inhibition on the survival of CML mice. 15 days after transplantation, mice harboring comparable 
leukemia loads (49±5 BCR-ABL1-GFP
+
Gr-1
+
 granulocytes/l blood) were randomized to 
monotherapy with either vehicle, imatinib or a blocking CD70 mAb (clone FR70) (34, 35) or 
CD70/imatinib combination therapy and disease development and survival were monitored. 
Monotherapy significantly delayed leukemia development and prolonged survival compared to the 
vehicle group; nevertheless, all animals eventually succumbed to CML. CD70/imatinib combination 
therapy significantly improved survival of CML mice compared to monotherapy, and 60% of the 
animals receiving the combination therapy were alive 90 days after transplantation (Fig. 6F). This 
suggested that CML stem/progenitor cells were completely eradicated or at least effectively controlled 
long-term in these mice. 
In order to investigate this issue, surviving mice were sacrificed and spleen weights and BM BCR-
ABL1-GFP
+
lin
-
 cell frequencies were determined. In this experiment, 1 out of 8 surviving mice 
displayed a splenomegaly; this and two other mice harbored detectable levels of BCR-ABL1-GFP
+
lin
-
 
cells in the BM, indicating the presence of CML (fig. S12A-B). Secondary transplantation of 1x10
7
 
whole BM (WBM) cells from these 3 mice induced fatal CML in lethally irradiated (2x6.5 Gy) BL/6 
recipients (Fig. 6G). In contrast, secondary recipients receiving WBM cells from the other 5 donors 
survived up to 90 days without signs of leukemia (Fig. 6G). This indicates that CD70/imatinib co-
treatment targeted and eliminated the disease-initiating LSCs in 5 out of 8 of the primary CML 
animals. 
The BCR-ABL1-GFP
+ 
LSK cell population that contains the LSCs is heterogeneous and hierarchically 
organized and can be further sub-divided into long-term (LT-)LSCs, short-term (ST-)LSCs and 
leukemia multipotent progenitors (MPPs) using the markers CD150, CD135 and CD48 (30, 36). To 
12 
 
analyze the impact of combination therapy on these LSC sub-populations in more detail, especially on 
the disease-initiating LT-LSCs (36), CML mice harboring comparable leukemia loads (163±20 
BCR/ABL-GFP
+
Gr-1
+
 granulocytes/l blood) 15 days after transplantation received either imatinib 
alone or CD70/imatinib combination therapy. 10 days later, mice were sacrificed and BM and spleen 
were analyzed. Compared to imatinib monotherapy, CD70/imatinib combination therapy resulted in 
significantly lower spleen weights and a lower leukemia load as indicated by lower numbers of BCR-
ABL1-GFP
+
Gr-1
+
 granulocytes in the blood as well as lower numbers of BCR-ABL1-GFP
+
lin
-
 
leukemia cells and BCR-ABL1-GFP
+
lin
-
c-kit
hi
 leukemia progenitors in the BM (fig. S12C-F). 
Importantly, CD70/imatinib combination therapy more efficiently eliminated the BCR-ABL1-GFP+ 
LSK cell population including the disease-initiating LT-LSCs than imatinib monotherapy (Fig. 6H-J 
and fig. S12G-H). 
In addition, lin
-
 BM cells from CD70/imatinib co-treated CML animals formed significantly fewer 
BCR-ABL1-GFP
+
 colonies than lin
-
 cells from imatinib-treated mice (Fig. 6K). To further prove that 
the findings from FACS analysis and colony assays in vitro actually account for reduced numbers of 
LSCs in vivo, 3x10
6
 WBM cells from imatinib- or CD70/imatinib-treated CML mice were 
transplanted into sublethally irradiated (4.5 Gy) secondary recipients. Recipients that received WBM 
cells from imatinib-treated leukemia mice all succumbed to CML. In contrast, 5 out of 6 mice 
receiving WBM cells from mice that had been treated with the CD70 mAb/imatinib combination 
therapy completely eliminated the disease and were alive 90 days after secondary transplantation 
without signs of leukemia (Fig. 6L).  
In summary, these data provide evidence that combination therapy using TKI and CD70/CD27 
inhibition selectively targets CML LSCs, particularly the disease-initiating LT-LSCs in vivo. 
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Discussion 
In myeloid leukemias, intrinsic and extrinsic factors mediate drug resistance in LSCs and constitute 
important barriers to current treatment strategies (37). Intrinsic drug resistance mechanisms, such as 
quiescence, the expression of ATP-binding cassette (ABC) transporters and pre-existing or acquired 
BCR-ABL1 mutations protect LSCs from both DNA-damaging agents and TKIs (1, 37, 38). Several 
approaches were proposed to overcome these intrinsic resistance mechanisms, including two-step 
therapy regimens using cell cycle-activating drugs followed by TKIs or chemotherapy (39) and the 
specific targeting of ABC transporters (40). Furthermore, next-generation TKIs with improved 
efficacy against mutated BCR-ABL1 were successfully developed and introduced into clinical practice 
(18). However, recent studies demonstrated that LSC survival and persistence are independent of 
BCR-ABL1 (3, 4) and therefore, even next-generation TKIs will most likely be ineffective against 
LSCs when used as monotherapy.  
In addition, accumulating evidence indicates that extrinsic factors from the BM microenvironment 
play an essential role in regulating LSC survival, self-renewal and drug resistance (37, 41). In analogy 
to HSCs, LSCs reside in and depend on BM niches consisting of cell types such as osteoblasts, 
mesenchymal stromal cells (MSCs) and endothelial cells (13, 42). These niche cells provide soluble 
and cell contact-dependent signals, including cytokines, chemokines, Wnt, Notch and Hedgehog 
ligands as well as integrins and cadherins that maintain LSC homeostasis (42). MSCs have been 
shown to support LSC adhesion and promote TKI resistance via N-cadherin and -catenin (43). 
Moreover, in leukemia, BM-infiltrating immune cells may contribute to the LSC niche and especially 
activated T cells interact with and paradoxically support LSCs (12, 13, 44).  
The canonical Wnt pathway is essential for the maintenance of stem cell characteristics of LSCs such 
as quiescence, self-renewal and the regulation of cell fate (8, 9). In CML, BCR-ABL1 induces 
stabilization of -catenin and thereby contributes to Wnt pathway activation (7). However, although 
BCR-ABL1-specific TKIs inhibit -catenin stability and thereby Wnt-signaling, it is well documented 
that LSCs are resistant to TKI treatment (3, 4). Here, we document that in response to TKI treatment 
and Wnt pathway inhibition, CML stem cells induce the expression of CD70. The CD70/CD27-
14 
 
interaction leads to compensatory Wnt pathway activation and thereby confers resistance of LSCs to 
TKI treatment. Under physiological conditions, CD70 is only expressed by activated lymphocytes and 
subsets of dendritic cells (10). In CML, activated CD70-expressing immune cells induced Wnt-
signaling in CD27-expressing LSCs, leading to disease progression (12). However, CD70 is also 
expressed after malignant transformation and has been detected on lymphomas and several solid 
tumors (10). CD70 was expressed at very low levels on malignant CML cells and was up-regulated on 
LSCs upon treatment with TKIs. Interestingly, it has been reported previously that CD70 expression is 
similarly induced upon irradiation on human glioblastoma and prostate carcinoma cells (45, 46). In 
response to TKI treatment, LSCs express both CD27 and CD70. Therefore, CD27-signaling could be 
induced in a cell-autonomous and/or paracrine manner. However, in vivo, LSCs are supposed to be a 
rare cell population present as single cells in the BM in a specialized niche microenvironment in 
analogy to HSCs (13, 42). Therefore, it is most likely that CD27-signaling triggered by CD70 is 
induced in a cell-autonomous manner. 
We found that BCR-ABL1 inhibition reduced miR-29 expression. Our data with lithium- or R-Spondin 
1-induced activation of the Wnt pathway are in agreement with earlier results in human MSCs 
indicating that Wnt-signaling directly increases miR-29 expression (47). Down-regulation of miR-29c 
increased the expression of its direct target SP1, a transcription factor with binding site in the CD70 
promoter (22) and SP1 knockdown prevented CD70 up-regulation in response to TKI. In addition, 
miR-29a,b down-regulation was associated with a reduced expression of DNMT1 leading to CD70 
promoter de-methylation. These combined effects resulted in CD70 up-regulation on LSCs, increased 
CD70/CD27-signaling and subsequently restored Wnt pathway activity (Fig. 7). We hypothesize that 
during BCR-ABL1 inhibition, constant CD70 expression on LSCs is needed to sustain compensatory 
Wnt-signaling. Therefore, blocking CD70/CD27-signaling in combination with TKIs synergistically 
inhibited the Wnt pathway and eradicated leukemia cells in vitro. More importantly, combination 
therapy effectively eliminated the disease-initiating LSCs in murine xenografts and in the murine 
CML model in vivo. However, because combination therapy resulted in the elimination of LSCs, we 
could not investigate whether CD70-triggered Wnt-signaling regulates CD70 expression. 
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In summary, our study indicates that blocking CD70/CD27-signaling in combination with TKI 
treatment overcomes compensatory Wnt activation and represents an attractive therapeutic strategy to 
specifically target CML LSCs. 
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Materials and Methods 
Study design  
In vitro experiments. In hypothesis-driven experimental designs, we addressed the molecular 
mechanisms of TKI-induced CD70 expression in CML cell lines and blood or BM samples from 
newly diagnosed CML patients treated in vitro with TKIs. Combination therapy using TKIs and 
blocking mAb was applied and its effect on Wnt pathway activation, CML cell growth and LSC 
activity was assessed. 
Mice. In hypothesis-driven experimental designs, we addressed the molecular mechanisms of TKI-
induced CD70 expression in LSCs in a murine model of CML and patient-derived xenografts using 
CD34
+
 stem/progenitor cells from newly diagnosed CML patients. Combination therapy using TKIs 
and blocking mAb was applied and its effect on Wnt pathway activation, leukemia development, 
survival, LSC proliferation and LSC activity was assessed. 
 
Antibodies and reagents for treatment 
Murine CD70 (clone FR70) was from BioXCell and control IgG from rat serum (rat-IgG) was from 
Sigma-Aldrich. Human CD27 (clone 1A4) and the corresponding isotype control (clone 15H6) were 
from Beckman Coulter. Human CD70 (clone 41D12-D) and a corresponding control mAb specific 
for the F protein of respiratory syncytial virus (Pavilizumab, Synagis
®
) were kindly provided by 
arGEN-X (Breda, The Netherlands). Imatinib and nilotinib were kindly provided by Novartis. 
Ponatinib was from Selleck Chemicals. Lithium chloride was from Sigma-Aldrich. Recombinant 
human R-Spondin 1 was from R&D Systems. 
 
Patient samples 
Peripheral blood samples and one BM aspirate from untreated, newly diagnosed CML patients at the 
Department of Hematology, Inselspital, University Hospital and University of Bern, Switzerland, were 
obtained after written informed consent. Patient characteristics are listed in table S1. Analysis of blood 
and BM samples was approved by the local ethical committee of the Canton of Bern, Switzerland. 
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In vitro experiments 
Cell lines. The human leukemia cell lines SD-1, K562, KBM5 and KBM5r have been described 
before (48-50). 
Liquid culture of primary human CD34
+
 CML stem/progenitor cells. CD34+ stem/progenitor cells 
of human CML patients were cultured and analyzed as previously described (44). 
Colony assays. Colony assays with FACS-purified CD34+ stem/progenitor cells from CML patients 
or MACS-purified BM lin
-
 cells from CML mice were performed as previously described (44). 
DNA methylation analysis of the CD70 promoter. Bisulfite conversion of isolated DNA samples 
from KBM5r cells were assessed using the Epitect
®
 Bisulfite Kit (Qiagen) according to the 
manufacturer’s protocol. The promoter region covering binding sites for important transcription 
factors was selectively amplified using the following primers: forward primer (-227 ~ -205): 5’-
GTTTTAGAAGAATGAGGTGGAG-3’; reverse primer (+14 ~ +35): 5’- 
TCAACCTATCAAAAAACCAAC-3’. For the amplification of bisulfite-treated genomic DNA 
(gDNA), the following PCR conditions were used: 1x 95°C for 10min; 40x 95°C for 30s, 58°C for 
40s, 72°C for 1min; 1x 72°C for 5min. The PCR cocktail consisted of 3l of DNA (of at least 10ng/l 
DNA for a final concentration of 3ng/l per reaction) in a 25l total volume using 0.5pmol of each 
primer, 200M dNTPs, 0.2U Hot Start Taq DNA polymerase, 1.5mM MgCl2 and the buffer supplied 
with the enzyme. The amplified promoter region was gel-purified and subjected for fluorescent Sanger 
sequencing (51). The relative quantification of the methylated allele (C) versus unmethylated allele (T) 
was assessed by the QSVAnalyser software (52). The ratio for methylated cytosine was used for the 
two-way hierarchical clustering analysis. The variable CpG fragments at the CD70 promoter were 
clustered based on pair-wise Euclidean distances and linkage algorithm for all of the 21 samples (7 
independent replicates per condition) as previously described (51). The procedure was performed 
using the double dendrogram function of the Gene Expression Statistical software (NCSS, Kaysville, 
Utah, USA). 
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Animal experiments 
Animal experiments were approved by the local experimental animal committee of the Canton of Bern 
and performed according to Swiss laws for animal protection. 
Mice. C57BL/6J (BL/6) mice were from RCC Ltd. (Füllinsdorf, Switzerland). NOD/LtSz-scid 
IL2Rnull (NSG) mice have been described before (31).  
Murine xenografts. 2x10
6
 MACS-purified CD34
+
 stem/progenitor cells from the blood of a newly 
diagnosed CML patient (patient 4) were injected i.v. into previously sublethally irradiated (2.75Gy) 
NSG mice. Starting one week after transplantation, imatinib (50mg/kg) was administered once daily 
by oral gavage. The CD70 mAb (clone 41D12-D) (10mg/kg) was administered i.p. every 3rd day. 
Sterile H2O and Synagis
® 
were used as control treatments. After 2 weeks of treatment, mice were 
euthanized and BM from femurs and tibias was analyzed by FACS for human cell engraftment using 
human CD45, CD34, CD33, CD3 and CD19 antibodies. 
Murine CML model. CML was induced and monitored as described (12, 44). Briefly, donor mice 
were treated with 150mg/kg of 5-fluorouracil intraperitoneally (i.p.). Six days later, BM was harvested 
and transduced twice with BCR-ABL1-GFP retrovirus by spin infection. 1x10
5
 cells were injected 
intravenously (i.v.) into the tail vein of sublethally irradiated (4.5 Gy) syngeneic recipients.  
Treatment of CML mice was started 15 days after transplantation. Imatinib (50mg/kg) was 
administered once daily by oral gavage. CD70 mAb (clone FR70) (300g/injection) was 
administered i.p every 3
rd
 day. Sterile H2O and rat-IgG were used as control treatments. 
To detect residual LSC activity in surviving CML mice (90 days after primary transplantation), 1x10
7 
whole BM (WBM) cells were injected i.v. into lethally irradiated (twice 6.5 Gy with 4 hours interval) 
recipient mice. 
To compare LSC activity in mice receiving imatinib monotherapy and vs. CD70/imatinib 
combination therapy, primary CML mice were treated for 10 days, were sacrificed and 3x10
6 
WBM 
cells were injected i.v. into sublethally irradiated (4.5 Gy) recipient mice. 
Leukemia stem cell analysis. Leukemia stem cell numbers in CML mice were analyzed by FACS as 
previously described (30, 44). Briefly, LSC sub-populations in lin
-
BCR-ABL1-GFP
+
 BM cells were 
defined as follows: LT-LSCs (Sca-1
+
c-kit
hi
CD135
-
CD48
-
CD150
+
); ST-LSCs (Sca-1
+
c-kit
hi
CD135
-
19 
 
CD48
-
CD150
-
); leukemia multipotent progenitor 1s (MPP1s: Sca-1
+
c-kit
hi
CD135
-
CD48
+
CD150
+
) and 
MPP2s (Sca-1
+
c-kit
hi
CD135
-
CD48
+
CD150
-
). 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism
®
 5.0 (GraphPad Software). The details of the 
test carried out are indicated in the figure legends. Data are represented as mean ± s.e.m and 
distributed approximately normally. Data were analyzed using one-way analysis of variance 
(ANOVA) and Tukey’s or Dunnett’s multiple comparison test, two-way ANOVA and Bonferroni 
post-test or student’s t-test (two-tailed). Significance of differences in Kaplan-Meier survival curves 
was determined using the log-rank test (two-tailed). In all cases, P < 0.05 was considered significant.  
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Fig. S1. TKI treatment induces CD70 expression on human BCR-ABL1
+
 leukemia cell lines.  
Fig. S2. TKI treatment mediates CD70 induction via BCR-ABL1 inhibition.  
Fig. S3. CD70 up-regulation is induced early after TKI treatment in KBM5r cells. 
Fig. S4. Activation of Wnt-signaling by lithium chloride or R-Spondin 1 restores TKI-mediated 
changes in gene expression.  
Fig. S5. BCR-ABL1 and CD70/CD27 co-inhibition reduces the expansion of KBM5 and KBM5r 
CML cells in vitro. 
Fig. S6. BCR-ABL1 and CD70/CD27 co-inhibition synergistically reduces cell growth and Wnt 
pathway activation in SD-1 cells.  
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-
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-
 LSKs.  
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Table S3. List of primers. 
 
 
 
 
 
 
21 
 
References and Notes 
1. E. Kavalerchik, D. Goff, C. H. Jamieson, Chronic myeloid leukemia stem cells. J Clin Oncol 
26, 2911-2915 (2008). 
2. B. J. Druker, M. Talpaz, D. J. Resta, B. Peng, E. Buchdunger, J. M. Ford, N. B. Lydon, H. 
Kantarjian, R. Capdeville, S. Ohno-Jones, C. L. Sawyers, Efficacy and safety of a specific 
inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344, 
1031-1037 (2001). 
3. A. S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M. W. Deininger, B. J. Druker, Human 
chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-
ABL activity. J Clin Invest 121, 396-409 (2011). 
4. A. Hamilton, G. V. Helgason, M. Schemionek, B. Zhang, S. Myssina, E. K. Allan, F. E. 
Nicolini, C. Muller-Tidow, R. Bhatia, V. G. Brunton, S. Koschmieder, T. L. Holyoake, 
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their 
survival. Blood 119, 1501-1510 (2012). 
5. M. Savona, M. Talpaz, Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 8, 
341-350 (2008). 
6. S. Faderl, M. Talpaz, Z. Estrov, S. O'Brien, R. Kurzrock, H. M. Kantarjian, The biology of 
chronic myeloid leukemia. N Engl J Med 341, 164-172 (1999). 
7. A. M. Coluccia, A. Vacca, M. Dunach, L. Mologni, S. Redaelli, V. H. Bustos, D. Benati, L. A. 
Pinna, C. Gambacorti-Passerini, Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia 
through its tyrosine phosphorylation. Embo J 26, 1456-1466 (2007). 
8. C. Zhao, J. Blum, A. Chen, H. Y. Kwon, S. H. Jung, J. M. Cook, A. Lagoo, T. Reya, Loss of 
beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12, 528-
541 (2007). 
9. F. H. Heidel, L. Bullinger, Z. Feng, Z. Wang, T. A. Neff, L. Stein, D. Kalaitzidis, S. W. Lane, 
S. A. Armstrong, Genetic and pharmacologic inhibition of beta-catenin targets imatinib-
resistant leukemia stem cells in CML. Cell stem cell 10, 412-424 (2012). 
22 
 
10. M. A. Nolte, R. W. van Olffen, K. P. van Gisbergen, R. A. van Lier, Timing and tuning of 
CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive 
responses and immunopathology. Immunol Rev 229, 216-231 (2009). 
11. A. Wiesmann, R. L. Phillips, M. Mojica, L. J. Pierce, A. E. Searles, G. J. Spangrude, I. 
Lemischka, Expression of CD27 on murine hematopoietic stem and progenitor cells. Immunity 
12, 193-199 (2000). 
12. C. Schürch, C. Riether, M. S. Matter, A. Tzankov, A. F. Ochsenbein, CD27 signaling on 
chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease 
progression. The Journal of clinical investigation 122, 624-638 (2012). 
13. C. Riether, C. M. Schürch, A. F. Ochsenbein, Regulation of hematopoietic and leukemic stem 
cells by the immune system. Cell death and differentiation 22, 187-198 (2015). 
14. I. S. Grewal, CD70 as a therapeutic target in human malignancies. Expert opinion on 
therapeutic targets 12, 341-351 (2008). 
15. Q. Lu, A. Wu, B. C. Richardson, Demethylation of the same promoter sequence increases 
CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 
174, 6212-6219 (2005). 
16. M. W. Deininger, Optimizing therapy of chronic myeloid leukemia. Exp Hematol 35, 144-154 
(2007). 
17. M. Koren-Michowitz, Y. Volchek, E. Naparstek, I. Gavish, I. Levi, J. M. Rowe, A. Shimoni, 
A. Nagler, Imatinib plasma trough levels in chronic myeloid leukaemia: results of a 
multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol 30, 200-205 (2012). 
18. T. O'Hare, W. C. Shakespeare, X. Zhu, C. A. Eide, V. M. Rivera, F. Wang, L. T. Adrian, T. 
Zhou, W. S. Huang, Q. Xu, C. A. Metcalf, 3rd, J. W. Tyner, M. M. Loriaux, A. S. Corbin, S. 
Wardwell, Y. Ning, J. A. Keats, Y. Wang, R. Sundaramoorthi, M. Thomas, D. Zhou, J. 
Snodgrass, L. Commodore, T. K. Sawyer, D. C. Dalgarno, M. W. Deininger, B. J. Druker, T. 
Clackson, AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently 
inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401-412 
(2009). 
23 
 
19. J. E. Cortes, H. Kantarjian, N. P. Shah, D. Bixby, M. J. Mauro, I. Flinn, T. O'Hare, S. Hu, N. I. 
Narasimhan, V. M. Rivera, T. Clackson, C. D. Turner, F. G. Haluska, B. J. Druker, M. W. 
Deininger, M. Talpaz, Ponatinib in refractory Philadelphia chromosome-positive leukemias. N 
Engl J Med 367, 2075-2088 (2012). 
20. C. M. Hedgepeth, L. J. Conrad, J. Zhang, H. C. Huang, V. M. Lee, P. S. Klein, Activation of 
the Wnt signaling pathway: a molecular mechanism for lithium action. Developmental biology 
185, 82-91 (1997). 
21. K. A. Kim, M. Wagle, K. Tran, X. Zhan, M. A. Dixon, S. Liu, D. Gros, W. Korver, S. 
Yonkovich, N. Tomasevic, M. Binnerts, A. Abo, R-Spondin family members regulate the Wnt 
pathway by a common mechanism. Mol Biol Cell 19, 2588-2596 (2008). 
22. S. Liu, L. C. Wu, J. Pang, R. Santhanam, S. Schwind, Y. Z. Wu, C. J. Hickey, J. Yu, H. 
Becker, K. Maharry, M. D. Radmacher, C. Li, S. P. Whitman, A. Mishra, N. Stauffer, A. M. 
Eiring, R. Briesewitz, R. A. Baiocchi, K. K. Chan, P. Paschka, M. A. Caligiuri, J. C. Byrd, C. 
M. Croce, C. D. Bloomfield, D. Perrotti, R. Garzon, G. Marcucci, 
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer 
cell 17, 333-347 (2010). 
23. M. Tan, J. Wu, Y. Cai, Suppression of Wnt signaling by the miR-29 family is mediated by 
demethylation of WIF-1 in non-small-cell lung cancer. Biochemical and biophysical research 
communications 438, 673-679 (2013). 
24. K. Kapinas, C. Kessler, T. Ricks, G. Gronowicz, A. M. Delany, miR-29 modulates Wnt 
signaling in human osteoblasts through a positive feedback loop. The Journal of biological 
chemistry 285, 25221-25231 (2010). 
25. J. K. Christman, 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: 
mechanistic studies and their implications for cancer therapy. Oncogene 21, 5483-5495 
(2002). 
26. F. Belloc, F. Moreau-Gaudry, M. Uhalde, L. Cazalis, M. Jeanneteau, F. Lacombe, V. Praloran, 
F. X. Mahon, Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells 
24 
 
through a Bim-dependant pathway modulated by cytokines. Cancer Biol Ther 6, 912-919 
(2007). 
27. T. C. Chou, Drug combination studies and their synergy quantification using the Chou-Talalay 
method. Cancer Res 70, 440-446 (2010). 
28. K. Silence, T. Dreier, M. Moshir, P. Ulrichts, S. M. Gabriels, M. Saunders, H. Wajant, P. 
Brouckaert, L. Huyghe, T. Van Hauwermeiren, A. Thibault, H. J. De Haard, ARGX-110, a 
highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and 
immune checkpoint blockade. MAbs 6, 523-532 (2014). 
29. B. Zhang, A. C. Strauss, S. Chu, M. Li, Y. Ho, K. D. Shiang, D. S. Snyder, C. S. Huettner, L. 
Shultz, T. Holyoake, R. Bhatia, Effective targeting of quiescent chronic myelogenous 
leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. 
Cancer Cell 17, 427-442 (2010). 
30. L. Li, L. Wang, Z. Wang, Y. Ho, T. McDonald, T. L. Holyoake, W. Chen, R. Bhatia, 
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in 
combination with imatinib. Cancer Cell 21, 266-281 (2012). 
31. L. D. Shultz, B. L. Lyons, L. M. Burzenski, B. Gott, X. Chen, S. Chaleff, M. Kotb, S. D. 
Gillies, M. King, J. Mangada, D. L. Greiner, R. Handgretinger, Human lymphoid and myeloid 
cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human 
hemopoietic stem cells. Journal of immunology 174, 6477-6489 (2005). 
32. A. Wilson, E. Laurenti, G. Oser, R. C. van der Wath, W. Blanco-Bose, M. Jaworski, S. 
Offner, C. F. Dunant, L. Eshkind, E. Bockamp, P. Lio, H. R. Macdonald, A. Trumpp, 
Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis 
and repair. Cell 135, 1118-1129 (2008). 
33. S. J. Neering, T. Bushnell, S. Sozer, J. Ashton, R. M. Rossi, P. Y. Wang, D. R. Bell, D. 
Heinrich, A. Bottaro, C. T. Jordan, Leukemia stem cells in a genetically defined murine model 
of blast-crisis CML. Blood 110, 2578-2585 (2007). 
25 
 
34. A. Nakajima, H. Oshima, C. Nohara, S. Morimoto, S. Yoshino, T. Kobata, H. Yagita, K. 
Okumura, Involvement of CD70-CD27 interactions in the induction of experimental 
autoimmune encephalomyelitis. J Neuroimmunol 109, 188-196 (2000). 
35. J. M. Kelly, P. K. Darcy, J. L. Markby, D. I. Godfrey, K. Takeda, H. Yagita, M. J. Smyth, 
Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 
3, 83-90 (2002). 
36. B. Zhang, Y. W. Ho, Q. Huang, T. Maeda, A. Lin, S. U. Lee, A. Hair, T. L. Holyoake, C. 
Huettner, R. Bhatia, Altered microenvironmental regulation of leukemic and normal stem cells 
in chronic myelogenous leukemia. Cancer Cell 21, 577-592 (2012). 
37. M. Y. Konopleva, C. T. Jordan, Leukemia stem cells and microenvironment: biology and 
therapeutic targeting. J Clin Oncol 29, 591-599 (2011). 
38. C. A. Huff, W. H. Matsui, B. D. Smith, R. J. Jones, Strategies to eliminate cancer stem cells: 
clinical implications. Eur J Cancer 42, 1293-1297 (2006). 
39. M. A. Essers, A. Trumpp, Targeting leukemic stem cells by breaking their dormancy. Mol 
Oncol 4, 443-450 (2010). 
40. M. Dean, T. Fojo, S. Bates, Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-
284 (2005). 
41. M. B. Meads, L. A. Hazlehurst, W. S. Dalton, The bone marrow microenvironment as a tumor 
sanctuary and contributor to drug resistance. Clinical cancer research : an official journal of 
the American Association for Cancer Research 14, 2519-2526 (2008). 
42. S. W. Lane, D. T. Scadden, D. G. Gilliland, The leukemic stem cell niche: current concepts 
and therapeutic opportunities. Blood 114, 1150-1157 (2009). 
43. B. Zhang, M. Li, T. McDonald, T. L. Holyoake, R. T. Moon, D. Campana, L. Shultz, R. 
Bhatia, Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase 
inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood 121, 1824-1838 (2013). 
44. C. Schürch, C. Riether, M. A. Amrein, A. F. Ochsenbein, Cytotoxic T cells induce 
proliferation of chronic myeloid leukemia stem cells by secreting interferon-gamma. The 
Journal of experimental medicine 210, 605-621 (2013). 
26 
 
45. J. Wischhusen, G. Jung, I. Radovanovic, C. Beier, J. P. Steinbach, A. Rimner, H. Huang, J. B. 
Schulz, H. Ohgaki, A. Aguzzi, H. G. Rammensee, M. Weller, Identification of CD70-
mediated apoptosis of immune effector cells as a novel immune escape pathway of human 
glioblastoma. Cancer Res 62, 2592-2599 (2002). 
46. M. B. Bernstein, C. T. Garnett, H. Zhang, A. Velcich, M. M. Wattenberg, S. R. Gameiro, S. 
Kalnicki, J. W. Hodge, C. Guha, Radiation-induced modulation of costimulatory and 
coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes 
productive antitumor immune interactions. Cancer Biother Radiopharm 29, 153-161 (2014). 
47. K. Kapinas, C. Kessler, T. Ricks, G. Gronowicz, A. M. Delany, miR-29 modulates Wnt 
signaling in human osteoblasts through a positive feedback loop. The Journal of biological 
chemistry 285, 25221-25231 (2010). 
48. S. Dhut, B. Gibbons, T. Chaplin, B. D. Young, Establishment of a lymphoblastoid cell line, 
SD-1, expressing the p190 bcr-abl chimaeric protein. Leukemia 5, 49-55 (1991). 
49. E. Klein, H. Ben-Bassat, H. Neumann, P. Ralph, J. Zeuthen, A. Polliack, F. Vanky, Properties 
of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 18, 
421-431 (1976). 
50. B. Scappini, S. Gatto, F. Onida, C. Ricci, V. Divoky, W. G. Wierda, M. Andreeff, L. Dong, K. 
Hayes, S. Verstovsek, H. M. Kantarjian, M. Beran, Changes associated with the development 
of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. 
Cancer 100, 1459-1471 (2004). 
51. R. Radpour, M. M. Haghighi, A. X. Fan, P. M. Torbati, S. Hahn, W. Holzgreve, X. Y. Zhong, 
High-throughput hacking of the methylation patterns in breast cancer by in vitro transcription 
and thymidine-specific cleavage mass array on MALDI-TOF silico-chip. Molecular cancer 
research : MCR 6, 1702-1709 (2008). 
52. I. M. Carr, J. I. Robinson, R. Dimitriou, A. F. Markham, A. W. Morgan, D. T. Bonthron, 
Inferring relative proportions of DNA variants from sequencing electropherograms. 
Bioinformatics 25, 3244-3250 (2009). 
53. H. Clevers, R. Nusse, Wnt/beta-catenin signaling and disease. Cell 149, 1192-1205 (2012). 
27 
 
 Acknowledgments 
We thank Karen Silence for helpful discussions and Jürg Schwaller for providing retroviral vectors.  
 
Funding 
 The Swiss National Science Foundation, the Swiss Cancer League, the Cancer League of the Canton 
of Bern, the Werner und Hedy Berger-Janser-Stiftung (A.F.O.), the Sassella Foundation (12/01), the 
Fondation BIOS pour la Recherche (C.R.), the Gertrud Hagmann-Stiftung für Malignomforschung, the 
SwissLife Jubiläumsstiftung, the Dr. Hans Altschüler-Stiftung, the Fondazione Dr. Carlo Gianella 
(C.M.S), the Mobiliar Jubiläumsstiftung, the Monika Kutzner Stiftung, the Stiftung Krebs-Hilfe and 
the Wolfermann-Nägeli Stiftung (C.R., C.M.S.).  
 
Author contributions  
C.R. and C.M.S. designed and performed experiments, analyzed and interpreted data and wrote and 
revised the manuscript. C.F., M.H., L.D., A.L.H. and R.R. performed experiments, analyzed and 
interpreted data and revised the manuscript. G.M.B. collected and contributed CML patient samples, 
interpreted data and revised the manuscript. A.F.O. designed experiments, analyzed and interpreted 
data and wrote and revised the manuscript.  
 
Competing interests  
The authors declare that they have no competing interests.  
 
Data and material availability  
Expression data are derived from a public repository for microarray data and are available under 
accession number E-MEXP-480 (http://www.ebi.ac.uk/arrayexpress). 
 
 
28 
 
Figure Legends 
 
 
Fig. 1: TKI treatment induces CD70 expression on human CML cell lines and human CD34
+
 
CML stem/progenitor cells. (A-E) 1x10
5
 KBM5 cells were cultured for 72h in the presence of 
vehicle (V: H2O) or imatinib (im) at the indicated concentrations. (A) Histograms and (B) mean 
fluorescence intensity (MFI) of CD70 protein expression (FACS). (C) CD70, (D) SP1, and (E) 
DNMT1 mRNA expression (qRT-PCR). (F-H) 1x10
4
 FACS-sorted CD34
+
 stem/progenitor cells from 
the blood of newly diagnosed CML patients were cultured in liquid culture for 7 days in the presence 
of vehicle or imatinib (1M). (F) CD70, (G) SP1 and (H) DNMT1 mRNA expression (qRT-PCR). (I-
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M) 1x10
5
 imatinib-resistant KBM5r cells were cultured for 72h in the presence of vehicle or ponatinib 
(po) at the indicated concentrations. (I) Histograms and (J) MFI of CD70 protein expression (FACS). 
(K) CD70, (L) SP1, and (M) DNMT1 mRNA expression (qRT-PCR). (N-P) 1x10
5
 KBM5r cells 
transfected with shSP1 (shSP1) or the respective control scrambled RNA lentiviral particles (scr) were 
cultured for 72h in the presence of vehicle or ponatinib (po, 0.1M). (N) MFI of CD70 protein 
expression (FACS). (O) CD70 and (P) SP1 mRNA expression (qRT-PCR). (B-E, J-M) Pooled data 
from two experiments run in duplicates and (N-P) data from one experiment run in duplicates are 
shown, respectively. Data are displayed as mean±s.e.m. Statistics: (B, J), one-sample t-test 
(hypothetical value 1); (C-H, K-P), student’s t-test. 
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Fig. 2: TKI-mediated BCR-ABL1 inhibition down-regulates miR-29 levels, leading to SP1 
expression and CD70 promoter de-methylation. (A-C) 1x10
5
 KBM5r cells were cultured in the 
presence of vehicle (V: H2O), imatinib (im, 1M), nilotinib (ni, 1M) or ponatinib (po, 0.1M) for 
72h and (A) miR-29a, (B) miR-29b and (C) miR-29c levels were determined (qRT-PCR). (D-E) 1x10
5
 
KBM5r cells were transfected with anti-miR-29a, anti-miR-29b or anti-miR-29c or scrambled control 
(scr) oligonucleotides for 48h and (D) SP1 and (E) DNMT1 mRNA expression was analyzed (qRT-
PCR). (F) Methylation status of the CD70 promoter at the SP1 transcription factor binding site of 
KBM5r cells upon treatment with vehicle, ponatinib (0.1M) or azacytidine (1M) as determined by 
bisulfite sequencing. (G) Heat map of relative quantification of methylated cytosines at five critical 
CpG sites in the CD70 promoter of KBM5r cells. (H) Semi-quantitative analysis of DNA methylation 
for CpG1 and CpG2 at the SP1 binding site. (A-C, D-E) Data from one experiment each, run in 
duplicates, are shown, respectively. (F-H) Pooled data from three independent experiments are shown. 
Data are displayed as mean±s.e.m. Statistics: student’s t-test. 
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Fig. 3: BCR-ABL1 and CD70/CD27 co-inhibition synergistically eradicates SD-1 leukemia cells. 
(A-F) 1x10
5
 SD-1 cells were cultured for 72h in the presence of either vehicle (V: H2O+IgG), 10g/ml 
of CD27 blocking mAb (A: H2O+CD27; clone 15H6), 1M of imatinib (im: im+IgG) or 1M of 
nilotinib (ni: ni+IgG) alone or both CD27/TKI in combination. (A, D) Cell numbers, (B, E) BrdU 
incorporation and (C, F) cell viability were determined by trypan blue staining and FACS. Apoptotic 
and necrotic cells were defined as Annexin-V
+
 and Annexin-V
+
7-AAD
+
 cells, respectively. (G) 1x10
5
 
SD-1 cells were treated with vehicle, CD27 or imatinib alone or in combination in a constant ratio. 
Cell numbers per well were counted after 72h and the effect of drug treatment was calculated as a ratio 
of vehicle-treated cells. (H-I) 1x10
5
 SD-1 cells were cultured in the presence of the compounds as 
described for (a-f) and activation of the Wnt pathway was assessed using (H) a TCF/LEF luciferase 
reporter assay after 24h and (I) by analysis for the expression of selected Wnt target genes after 72h 
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(qRT-PCR). One representative experiment out of two run in duplicates is shown for each panel. RLU, 
relative luminescence units. Data are displayed as mean±s.e.m. Statistics: (A, D), two-way ANOVA; 
(B, E, H), one-way ANOVA.  
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Fig. 4: CD70 mAb/imatinib combination treatment eradicates human CD34+ CML 
stem/progenitor cells in vitro. (A-E) 1x10
4
 MACS-purified CD34
+
 stem/progenitor cells of newly 
diagnosed CML patients from blood (n=3) or BM (n=1) were cultured in duplicates in liquid culture in 
the presence of 10g/ml of IgG (IgG) or CD70 blocking mAb (A: clone 41D12-D). (A, B) 
Histograms and (C, D) mean fluorescence intensities (MFI) of CD27 and CD70 expression on CD34
+
 
CML stem/progenitor cells. (E) Soluble CD27 (sCD27) levels in supernatants after 7 days of culture. 
(F-J) 1x10
4
 FACS-sorted CD34
+
 cells were cultured in duplicates in liquid culture in the presence of 
vehicle (V: H2O+IgG), 10g/ml of CD70 (A: H2O+CD70), 1M of imatinib (im: im+IgG) or both 
in combination (A/im: CD70+imatinib). (F) Cell numbers, (G) BrdU incorporation and (H, I) cell 
viability were determined by trypan blue staining and FACS after 7 days. Apoptotic and necrotic cells 
were defined as Annexin-V
+
 and Annexin-V
+
7-AAD
+
 cells, respectively. (J) Duplicates of 4x10
3
 
FACS-sorted CD34
+
 CML stem/progenitor cells were cultured overnight in 96-well V-bottom plates 
in the presence of the compounds as described for (B-K) and were then transferred into 
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methylcellulose containing the respective drugs. Colony formation was determined after 14 days by 
inverted light microscopy. Statistics: (C, D) one-sample t-test (hypothetical value 1); (E), student’s t-
test; (F-J) one-way ANOVA.  
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Fig. 5: CD70 mAb/imatinib combination therapy eradicates human CD34+ CML 
stem/progenitor cells in murine xenografts in vivo. (A-E) 2x10
6
 MACS-purified CD34
+
 
stem/progenitor cells from the blood of three newly diagnosed CML patients were injected 
intravenously into irradiated (2.75Gy) NSG mice. Starting one week after transplantation, imatinib 
(im, 50mg/kg) was administered once daily by oral gavage. 10mg/kg of CD70 (A) was administered 
intraperitoneally every 3
rd
 day. Sterile H2O and a control mAb specific for the F protein of respiratory 
syncytial virus (Pavilizumab, Synagis
®
) were used as mock-treatment (V). (B) After 2 weeks of 
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treatment, mice were euthanized and BM was analyzed for human cells by FACS. (C) Frequencies 
and (D) absolute numbers of human CD45
+
CD33
+
 CML myeloid cells and (E) absolute numbers of 
human CD45
+
CD34
+
 CML stem/progenitor cells in the BM. (F) MFI of CD70 expression on 
CD45
+
CD34
-
 CML cells and CD45
+
CD34
+
 CML stem/progenitor cells in xenografted NSG mice (n=3 
per xenograft and per treatment). (G) CD70, (H) SP1, (I) DNMT1 mRNA and (J-L) miR-29 
expression (qRT-PCR) in CD34
+
 cells. (M, N) Correlation of CD70 expression with the expression of 
selected Wnt target genes (M) RUNX1 and (N) WISP1 in CD34
+
 stem/progenitor cells from newly 
diagnosed chronic phase CML patients. Expression data are derived from a public repository for 
microarray data and are available under accession number E-MEXP-480 
(http://www.ebi.ac.uk/arrayexpress). Data are displayed as mean±s.e.m. Statistics: (C-E) one-way 
ANOVA; (F-L) student’s t-test; (M, N) Pearson’s correlation.  
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Fig. 6: CD70 mAb/imatinib combination therapy eradicates LSCs and promotes long-term 
survival of CML mice. (A-E) BL/6 CML mice were treated with vehicle (V: H2O, n=5) or 50mg/kg 
of imatinib (im, n=7) once daily by oral gavage starting 15 days after transplantation. 10 days later, 
CD70 protein expression was analyzed by FACS in BCR-ABL1-GFP
+
 LSKs and endogenous GFP
-
 
LSKs. (A) Representative histograms, (B) mean fluorescence intensity (MFI). (C) Cd70, (D) Sp1 and 
(E) Dnmt1 mRNA expression in FACS-sorted, pooled BCR-ABL1-GFP
+
 LSKs (qRT-PCR). (F) 
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Kaplan-Meier survival curves of primary BL/6 CML mice. Starting 15 days after transplantation, 
imatinib (50mg/kg) was administered once daily by oral gavage. 300g of CD70 blocking mAb 
(clone FR70) were administered intraperitoneally every 3
rd
 day. Sterile H2O and IgG from rat serum 
were used as controls. Pooled data from 2 independent experiments with n=11-15 mice per group are 
shown. (G) Survival of lethally irradiated (2x6.5 Gy) secondary recipients (n=8) that received 1x10
7
 
whole BM (WBM) cells from CD70/im treated primary CML mice (n=8) that were alive 90 days 
after primary transplantation. Data from one primary transplantation experiment with n=8 surviving 
animals are shown. (H-L) Primary BL/6 CML mice were treated with either imatinib alone (n=5) or 
with the combination therapy (n=6) as described in (f) starting 15 days after transplantation. 10 days 
later, numbers of (H) BCR-ABL1-GFP
+
 LSKs, (I) BCR-ABL1-GFP
+
 LT-LSCs (LSK CD135
-
CD48
-
CD150
+
) and (J) BCR-ABL1-GFP
+
 ST-LSCs (LSK CD135
-
CD48
-
CD150
-
) were determined in the 
BM (FACS). (K) Equal numbers of total lin
-
 cells were plated in methylcellulose and BCR-ABL1-
GFP
+
 colonies were enumerated 7 days later by inverted fluorescence microscopy. (L) 3x10
6
 WBM 
cells were transplanted into sublethally irradiated (4.5 Gy) recipient mice and survival was monitored. 
(F, G, L) Numbers of mice that succumbed to CML of total transplanted mice are indicated. Data are 
displayed as mean±s.e.m. Statistics: (B, H-K), student’s t-test; (F,L), log-rank test.  
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Fig. 7: Hypothesis of how combination therapy affects the Wnt pathway. The Wnt pathway is 
crucial for LSC survival and maintenance (8, 9). During homeostasis, the absence of Wnt 
ligand/Frizzled receptor signaling leads to -catenin degradation via the proteasome (53). (A) In CML, 
the Wnt pathway is constantly active even in the absence of Wnt ligands because of BCR-ABL1-
mediated -catenin stabilization/activation (7). (B) TKI treatment reduces BCR-ABL1-mediated Wnt 
pathway activation but simultaneously represses miR-29s. Down-regulation of miR-29c results in SP1 
up-regulation, whereas miR-29a,b down-regulation is associated with a decrease in DNMT1 
expression leading to CD70 promoter DNA de-methylation. Together, these effects increase the 
expression of CD70, resulting in CD27-signaling and compensatory Wnt pathway activation. (C) 
Blocking of CD70/CD27-signaling by mAb in combination with TKI treatment synergistically inhibits 
the Wnt pathway and leads to LSC eradication. Solid lines, direct effects; dashed lines, indirect 
effects. 
 
 
 
 
 
 
